000 03721naa a22005657i 4500
001 UMUN-OA-20261005-PH-035
003 local
005 20261005174914.0
006 m o d
007 cr||||||||||||
008 261005s2021 xx o u000 0 eng d
024 7 _a10.3390/cancers13174287
_2doi
035 _a(local)EuropePMC:PMC8428369
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aSergiusz Łukasiewicz
_eauthor.
245 1 0 _aBreast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. /
_cSergiusz Łukasiewicz; Marcin Czeczelewski; Alicja Forma [and others].
264 1 _a[Place of publication not identified] :
_bMultidisciplinary Digital Publishing Institute (MDPI),
_c2021.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aBreast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020. Its incidence and death rates have increased over the last three decades due to the change in risk factor profiles, better cancer registration, and cancer detection. The number of risk factors of BC is significant and includes both the modifiable factors and non-modifiable factors. Currently, about 80% of patients with BC are individuals aged >50. Survival depends on both stage and molecular subtype. Invasive BCs comprise wide spectrum tumors that show a variation concerning their clinical presentation, behavior, and morphology. Based on mRNA gene expression levels, BC can be divided into molecular subtypes (Luminal A, Luminal B, HER2-enriched, and basal-like). The molecular subtypes provide insights into new treatment strategies and patient stratifications that impact the management of BC patients. The eighth edition of TNM classification outlines a new staging system for BC that, in addition to anatomical features, acknowledges biological factors. Treatment of breast cancer is complex and involves a combination of different modalities including surgery, radiotherapy, chemotherapy, hormonal therapy, or biological therapies delivered in diverse sequences.
540 _aCreative Commons Attribution. See the linked licence for the applicable terms.
_uhttps://creativecommons.org/licenses/by/4.0/
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Public Health.
650 4 _aClassification
650 4 _aBreast cancer
650 4 _aDiagnosis
650 4 _aPrognosis
650 4 _aTreatment
650 4 _aMarker
653 _aB. Sc. Public Health
653 _aUMUN open access collection
653 _aepidemiology
655 4 _aReview articles.
700 0 _aMarcin Czeczelewski
_eauthor.
700 0 _aAlicja Forma
_eauthor.
700 0 _aJacek Baj
_eauthor.
700 0 _aRobert Sitarz
_eauthor.
700 0 _aAndrzej Stanisławek
_eauthor.
773 0 _tCancers
_gVol. 13, no. 17, (2021), pages/article 4287
_x2072-6694
856 4 0 _uhttps://europepmc.org/articles/PMC8428369
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC8428369
_qlocal
942 _n0
999 _c1307
_d1307